SUNRISE, Fla., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today it has filed with appropriate agencies in Switzerland for reimbursement approval for its MyoCell(r) myogenic cell therapy for heart failure. Bioheart has approval to treat patients with MyoCell cell therapy at the Kantonsspital Luzern (Hospital in Luzern, Switzerland) with Prof. Paul Erne as the principal investigator. This patented composition and method has been studied in clinical trials involving more than 350 patients to date at over 100 centers worldwide since the year 2000. Data from one of these trials conducted by Bioheart indicates that about 84 percent of the myogenic stem cell treated patients improve in quality of life and exercise capacity. In comparison, in trials involving control patients, only 31 percent of patients on heart failure drugs improved.
